Press Releases

Liquidia Announces Chief Financial Officer Transition

Steven Bariahtaris Appointed Interim Chief Financial Officer RESEARCH TRIANGLE PARK, N.C. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its
Aug 20, 2020

Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

RESEARCH TRIANGLE PARK, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal
Aug 05, 2020

Liquidia Announces Closing of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C. , July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced the closing of its
Jul 02, 2020

Liquidia to Host Conference Call to Provide Update on Recent Announcements

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, will host a webcast and
Jun 29, 2020

Liquidia Announces Pricing of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced the pricing of an
Jun 29, 2020

Liquidia Announces Proposed Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced today that it has
Jun 29, 2020
Displaying 21 - 30 of 87